Robinson James JR. Increases Stake in URGN
Robinson James JR. bought 10,000 shares of URGN on June 22, 2026.
Key Points
- Robinson James JR. bought 10,000 shares of URGN on June 22, 2026, at an undisclosed price.
- URGN shares traded near $35.8 on Wednesday, with analysts maintaining buy ratings and targets up to $45.
- Insiders, including Robinson James JR., collectively purchased shares, indicating ongoing interest in URGN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robinson James JR. recently increased his stake in URGN by purchasing 10,000 shares on June 22, 2026. Although the price and total value of the transaction weren't disclosed, this move adds to his existing holdings in the company.
Other Institutional Activity in URGN
Several institutional investors have also adjusted their positions in URGN. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at about $51.16 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth approximately $47.05 million. Kynam Capital Management, LP also initiated a stake, acquiring 2,247,393 shares valued at around $40.41 million. Meanwhile, Morgan Stanley slightly reduced its position by 2,863 shares, now holding 2,560,038 shares worth $46.03 million.
UroGen Pharma Ltd. Stock Down 18.4%
Shares of URGN traded near $35.8 on Wednesday. While specific financial ratios like P/E were not provided, the stock's recent trading activity and analyst ratings suggest continued interest from both institutional and retail investors.
$URGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders purchased shares of URGN. Robinson James JR. bought 10,000 shares, while other insiders, including Leana Wen and Arie Belldegrun, also made significant purchases. Each insider's transaction was not part of a pre-planned trading program, indicating a potential personal conviction in the company's prospects.
Analysts Set New Price Targets
Analysts remain bullish on URGN. On May 11, 2026, HC Wainwright & Co. maintained a buy rating with a price target of $45. Oppenheimer also maintained its buy rating on May 7, 2026, with a target of $40. These ratings reflect confidence in URGN's future performance.
Bottom Line
Robinson James JR.'s purchase of URGN shares suggests confidence in the company's future. Institutional investors are also adjusting their positions, which could indicate broader market sentiment. Analysts continue to support the stock with buy ratings and optimistic price targets. As always, these insider and institutional moves are backward-looking and may not reflect current positions.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.